PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,319,254
|
pinna enhanc angular discrimin frontal hemifield human sound local horizont dimens thought domin binaur cue particular interaur time delay monaur local dimens relat poor remain ambigu front versus back versus distinguish high frequenc spectral cue generat pinna experi studi show account incomplet use binaur listen throughout pinna substanti enhanc horizont discrimin frontal hemifield make discrimin front better discrimin rear particular direct away median plane elimin acoust effect pinna acoust bypass low pass filter abolish advantag front without affect rear acoust measur reveal pinna induc spectral promin shift smooth frequenc sound move azimuth improv perform discuss term monaur binaur chang induc pinna
|
D013017
|
T041
|
36,319,253
|
speech nois test innov applic pediatr patient underrepres popul fit duti clinic trial remot servic speech percept test defin provid standard speech stimuli requir listen provid behavior score respons integr part audiolog test batteri sinc begin audiolog profess past sever decad limit diagnost prognost valid standard speech percept test routin administ clinic note promot speech nois test highlight review summar emerg innov approach speech nois test focus five applic pediatr consider promot measur sensori cognit compon separ appropri serv underrepres popul special attent racial ethnic linguist minor well consid biolog sex andor gender differ variabl interest binaur fit duti assess function hear occup set demand abil detect recogn local sound util speech nois test pharmacotherapeut clinic trial consider drug mechanist action patient popul studi design onlin mobil applic hear assess increas access direct consum market
|
D013067
|
T041
|
36,319,250
|
predict model crowd nois larg wait hall crowd nois usual primari nois larg wait hall difficult predict influenc sever factor room acoust crowd characterist studi develop crowd nois predict model base superposit direct reverber sound energi use factor spatial layout wait hall number distribut crowd behavior ratio ratio vocal passeng total number passeng averag crowd sound power verifi model site measur conduct two larg wait hall obtain necessari input paramet crowd nois level one wait hall obtain nois level data exclud broadcast period method determin individu averag sound power base model also present found approxim db final model verifi use measur data show model could accur predict averag crowd nois level chang trend crowd nois tempor spatial dimens averag r squar approxim averag differ approxim dba predict measur result
|
D009622;D000162
|
T070;T069;T067
|
36,319,249
|
perceptu detect threshold numer dispers binaur aural two acoust differ room room acoust simul use finit differ time domain method wide frequenc rang comput expens typic contain numer dispers numer dispers audibl thus constitut artifact aural need measur perceptu threshold numer dispers achiev optim balanc comput complex audibl dispers work measur perceptu detect threshold numer dispers binaur aural two acoust differ room numer dispers incorpor measur binaur room impuls respons brir mean filter repres dispers plane wave experi propag simul direct worst case dispers error result show perceptu detect threshold general lower reverber room great depend sourc signal independ room threshold measur notic pure brir ie impuls sourc signal almost unnotic speech result also show statist evid perceptu threshold condit numer dispers present absent direct path brir differ
|
D000162;D013067
|
T070;T041
|
36,319,248
|
medial olivocochlear reflex reliabl effect averag presenc synchron spontan otoacoust emiss medial olivocochlear reflex mocr usual assess inhibit transient evok otoacoust emiss teoae contralater nois small effect understand origin mocr crucial obtain data highest accuraci ie high signal nois ratio snr turn larg depend number signal averag studi investig reliabl mocr measur affect number averag time effect presenc synchron spontan otoacoust emiss ssoae taken account known factor signific affect teoae amplitud snrs record session consist two seri four measur allow comparison mocr magnitud base averag reliabl base compar two seri result show good qualiti mocr measur ie intraclass correl requir number averag least doubl obtain standard teoae test ie compar ear without ssoae need higher number averag reach correl ear ssoae
|
D017084;D012018
|
T042
|
36,319,245
|
impact infauna worm tube shell hash sediment acoust variabl deviat viscous grain shear model infauna influenc geoacoust paramet surfici marin sediment investig effect experi conduct natur sand silt sediment northern gulf mexico situ acoust measur sediment sound speed attenu shear speed perform sediment core collect upper cm seab laboratori measur sound speed attenu core conduct core content analyz biolog physic properti sinc model current account effect infauna deviat model predict expect assess extent acoust measur compar viscous grain shear model buckingham j acoust soc j acoust soc depth depend profil sediment poros mean grain size measur core use input paramet comparison acoust result distribut infauna worm tube shell hash suggest biogen impact acoust variabl model accuraci import surfici marin sediment presenc infauna worm tube correl higher variabl sound speed attenu greater deviat model near sediment water interfac
|
D019015;D000162
|
T068;T070
|
36,319,244
|
detect probabl densiti estim fin whale seaglid singl hydrophon ocean glider deploy within cabl hydrophon array demonstr framework estim popul densiti fin whale balaenoptera physalus passiv acoust glider array use estim track acoust activ whale track becam detect trial model detect function glider record window contain fin whale hz puls use general addit model detect probabl depend horizont distanc low frequenc glider flow nois median hz spectral level db pa hz detect probabl near one horizont distanc zero effect detect radius km coeffici variat cv use estim acoust avail acoust activ group size tag track fin whale respect densiti fin whale estim whale per km cv plot sampl densiti estim area time estim array data alon whale per km cv present densiti estim small demonstr experi use caution framework present advanc understand potenti use glider cetacean densiti estim
|
D050617
|
T015
|
36,319,243
|
tempor spectral characterist convers versus read fricat american english present studi compar product fricat convers versus read speech american english goal examin paramet contribut identif fricat across two speech style studi survey fricat token buckey corpus pitt johnson hume kiesl raymond speech commun timit corpus zue seneff recent research toward advanc man machin interfac spoken languag elsevi amsterdam netherland pp total differ tempor spectral measur test includ segment durat preced follow phone durat spectral moment onset midpoint andor offset spectral peak frequenc etc result show segment durat midpoint spectral moment make promin contribut categor fricat speech style spectral measur import convers speech wherea durat play greater role read speech time magnitud differ across speech style often low mani observ effect may attribut methodolog differ across corpora result may indic reduct fricat convers speech limit compar reduct type speech sound plosiv
|
D007802;D013067
|
T171;T041
|
36,319,242
|
perfluorocarbon nanodroplet size acoust vapor inerti cavit affect lipid shell composit vitro perfluorocarbon nanodroplet pfcnds ultrasound contrast agent phase transit liquid nanodroplet gas microbubbl activ laser irradi inson ultrasound puls dynam pfcnds vari drastic depend nanodroplet composit includ lipid shell properti paper investig effect vari ratio pegyl non pegyl phospholipid outer shell pfcnds acoust nanodroplet vapor liquid gas phase transit inerti cavit rapid collaps vapor nanodroplet dynam vitro inson focus ultrasound nanodroplet high concentr pegyl lipid larger diamet exhibit greater varianc size distribut compar nanodroplet lower proport pegyl lipid lipid shell pfcnds lipid shell compos pegyl non pegyl lipid yield highest b mode imag intens durat well greatest pressur differ acoust droplet vapor onset inerti cavit onset demonstr slight chang lipid shell composit pfcnds signific impact droplet phase transit inerti cavit dynam find help guid research fabric pfcnds optim composit specif applic
|
D005466
|
T109
|
36,319,241
|
supra threshold deficit normal hear militari recruit expos impuls nois aim studi determin effect impuls nois exposur various proxi measur cochlear synaptopathi young militari recruit total militari recruit exposur firearm artilleri nois non expos particip recruit present normal hear threshold presenc distort product otoacoust emiss dpoae nois exposur structur interview nesi use quantifi nois exposur speech percept nois spin equival rectangular bandwidth erb auditori filter auditori brainstem respons wave amplitud wave amplitud growth function wave iv amplitud ratio wave v latenc wave v latenc shift ipsilater nois summat potentialact potenti ratio electrocochleographi measur militari particip spin wors erb khz larger wave amplitud dbnhl reduc wave v latenc delay howev signific correl observ nesi auditori measur multipl test control result suggest militari recruit may exhibit supra threshold deficit despit present normal hear threshold presenc dpoae futur studi includ measur auditori filter test batteri
|
D017084;D008889
|
T097;T042
|
36,319,240
|
overturn mechan cochlear amplif via area deform organ corti mammalian ear emb cellular amplifi boost sound induc hydromechan wave propag along cochlea oper amplifi fulli understood difficult disentangl experiment prevail view cochlear wave amplifi piezo electr action outer hair cell ohc whose cycl cycl elong contract inject power local motion basilar membran bm concomit deform oppos top side organ corti assum play minor role general neglect howev analysi intracochlear motion obtain use optic coher tomographi call prevail view question particular analysi suggest net local power transfer ohc bm either negat high ineffici ii vibrat top side organ corti play primari role travel wave amplif phenomenolog model deriv observ manifest realist cochlear respons suggest amplif aris almost entir ohc induc deform top side organ corti effect model turn classic assumpt spatial imped relat power flow direct within sensori epithelium upsid
|
D009925;D003051
|
T023
|
36,319,239
|
reconsid later vocalis evid percept product australian english l later vocalis assum aris chang coron articul typic characteris perceptu without link vocalis percept coron articul therefor examin listen percept coda l vocalis relat coron closur perceptu stimuli acquir record later produc six speaker australian english use electromagnet articulographi ema tongu tip closur monitor later ema data increas incid incomplet coron closur found coda l relat onset l verifi dataset includ l token produc incomplet coron closur primari articulatori cue vocalis l conduct percept studi four high experienc auditor rate coda l token vocalis non vocalis ordin mix model show increas tongu tip tt apertur delay correl vocalis percept auditor rate characteris lack inter rater reliabl correl increas tt apertur delay vocalis percept show reliabl auditori classif variat auditor suggest listen may sensit differ set cue associ later vocalis yet entir understood
|
D007802;D013067
|
T171;T041
|
36,319,233
|
intellig detect speech measur diotic dichot group listen slight hear loss purpos investig determin group listen threshold khz exceed db hl slight hear loss would exhibit degrad perform target stimuli mask token speech intellig threshold detect threshold measur separ speech mask flat spectrum nois speech shape nois noso nos configur employ consist find earlier investig masker speech token broadband noso nos detect threshold substanti lower intellig threshold import small cohort test mean threshold obtain db db group equival masker speech target high pass filter hz mean intellig threshold obtain db group db higher obtain db group independ masker type interaur configur stimuli real world listen situat deficit may manifest substanti reduc speech intellig perhap increas listen effort listen whose threshold khz exceed db hl slight hear loss
|
D034381;D013067;D003638
|
T033;T184;T047;T041
|
36,319,232
|
prospect measur hear threshold militari rifl train ear protect nois exposur monitor although causal relationship exist militari occup nois exposur hear loss research struggl identifi andor character specif oper nois exposur produc measur chang hear function short follow exposur grow evid suggest current standard nois exposur limit good predictor true hear damag studi aim captur dose respons relationship militari rifl train exercis nois exposur hear threshold captur exposur wearabl system capabl measur impuls nois simultan bodi ear behind hear protect use character hear threshold chang portabl audiometri employ within h exposur median h time weight protect free field equival ear exposur dba one site dba second site signific dose respons correl ear nois exposur postexposur hear threshold chang across popul r p observ result demonstr approach establish damag risk criteria drc ear protect measur base hear threshold chang ear drc current exist may critic predict risk injuri nois environ protect mandatori fit status vari
|
D009623;D006317;D008889;D016273
|
T097;T037;T067
|
36,319,231
|
visual attent affect reliabl otoacoust emiss medial olivocochlear reflex studi investig whether visual attent affect reliabl ie repeat transient evok otoacoust emiss teoae magnitud medial olivocochlear reflex mocr estim teoae measur three visual attent condit control subject seat eye close passiv subject look pattern squar comput screen activ subject silent count occasion invert pattern estim reliabl whole record session repeat next day result show visual attent signific affect teoae mocr magnitud reliabl therefor possibl employ visual stimuli eg watch silent movi teoae experi procedur sometim use test prevent subject fall asleep keep children still quiet
|
D017084;D012018
|
T042
|
36,319,229
|
engag capston project collabor approach case studi psychoacoust undergradu spanish univers conclud scienc degre capston project cp must appli knowledg gain studi recent year student technic degre often postpon last step due fast entri labour market disappoint develop capston project articl present approach tri overcom challeng avoid delay project submiss call engag capston project author support french compani eomi manag educ project student becom respons contribut free open softwar project call mosqito provid sound qualiti metric base psychoacoust framework provid ensur involv project student academicindustri supervisor help avoid student discourag propos methodolog compar current program learn propos expect outcom extens explain experi gather date limit result obtain show potenti applic propos engag capston project solut late cp submiss
|
D003479;D007858
|
T061;T062;T170;T065;T041
|
36,319,228
|
broadband acoust quantif mix biolog aggreg new england shelf break new england shelf break cold less salin shelf water collid warmer saltier slope water form distinct oceanograph front offic naval research sediment character experi front map narrowband khz broadband khz shipboard echo sounder acoust determin cross shelf veloc front rang amplitud ms acoust survey reveal aggreg scatter near foot front acoust backscatt conjunct northeast fisheri scienc center bottom trawl survey identifi longfin squid doryteuthi pealeii mackerel scomber scombrus like scatter aggreg mix speci scatter model develop refin use match method use distribut length speci mean length squid mackerel respect use match method cm compar cm trawl data estim total biomass aggreg factor time larger use match method estim length distribut compar trawl length distribut
|
D005398;D010473
|
T092;T013
|
36,319,226
|
room impuls respons databas multizon sound field reproduct l letter introduc databas room impuls respons rir measur seven differ room multizon sound field reproduct research various acoust environ circular array loudspeak instal room two microphon array place sequenti five differ zone insid loudspeak array total rir measur establish databas demonstr applic databas multizon sound field reproduct simul perform pressur match acoust contrast control method investig system optim rir measur one room would perform room
|
D008962;D013016
|
T062;T170;T070
|
36,319,225
|
detect dynam chang interaur delay older adult l abil older adult relat intact low frequenc hear detect motion acoust sourc investig use dynam vari interaur delay threshold measur use singl interv two altern forc choic task listen determin sound sourc move stationari motion threshold signific larger stationari local threshold correl observ age motion detect abil age rang test interest find similar threshold older younger adult result suggest relianc domin low frequenc binaur time cue unaffect high frequenc hear loss older adult
|
D001307;D013017
|
T041
|
36,319,224
|
one one adapt staircas procedur speech nois test standard error measur fluctuat track one one adapt staircas procedur often use estim speech recognit threshold srt speech nois test articl provid brief histor overview one one procedur psychophys discuss groundbreak earli work still relev clinic audiolog scientif research next articl focus two aspect one one adapt procedur first standard error measur sem second fluctuat track ie standard deviat signal nois ratio stimuli within track sd track simul ideal non ideal listen experiment data use determin evalu differ relationship paramet slope speech recognit function srt sem sd track hear loss non ideal behavior inattent fatigu give task becom difficult slight increas averag valu sd track sd track howev poor discrimin reliabl unreli srt estim
|
D013060;D013067
|
T041;T040;T054
|
36,319,220
|
perceptu adapt novel accent phonet categori expans categori shift listen rapid adapt unfamiliar accent exampl follow exposur speaker whose f sound ambigu f categor sound along f phonet continuum f investig adapt mechan under perceptu chang listen shift target sound phonet space categori shift adopt general mechan broaden categori categori expans experi train listen accent contain ambigu test categor phonet continua span f listen test continua show signific increas proport respons vs control test f experi investig acoust phonet similar may modul mechan under recalibr listen train accent experi test differ continuum time train listen show signific increas proport respons novel phonet contrast suggest phonet recalibr involv degre non uniform categori expans constrain phonet similar train test sound
|
D010700;D013067
|
T090;T068;T041
|
36,319,217
|
larg scale simul bird local system forest distribut microphon array acoust wildlif monitor system import tool captur inform anim habit ecosystem previous work demonstr effect audio base bird local techniqu howev studi investig perform robust distribut system larg forest perform distribut microphon array local bird examin simul forest scene ad reverber ambient nois measur error simul reveal import signal nois ratio spectral weight local algorithm result may guid design larg scale wildlif monitor system suggest promis direct improv
|
D017753;D009622
|
T067;T070;T069;T082
|
36,319,216
|
hear aid delay open fit devic prefer sound qualiti listen normal impair hear key factor influenc sound qualiti open fit digit hear aid process delay far delay limit need ensur optim rather toler sound qualiti establish use realist hear aid simul current studi investig relationship prefer sound qualiti five process delay rang ms listen normal impair hear listen normal hear show strong prefer shortest delay listen impair hear particip mild hear loss khz also prefer shortest delay
|
D006310
|
T074
|
36,319,215
|
canon correl analysi statist method relat underwat acoust propag ocean fluctuat numer model current use understand environment fluctuat impact acoust propag process tedious complex fluctuat environ letter propos complementari approach base upon canon correl analysi cca determin statist relationship two set observ acoust oceanograph variabl shown exampl cca put forward impact extern intern tide shallow water propag result consist physic understand tide impact acoust propag encourag use cca complex studi particular environ fluctuat sever environment phenomena
|
D000089342;D008962
|
T062;T081;T170
|
36,319,214
|
virtual realiti head mount display affect sideton percept purpos studi investig whether head mount display hmds chang sideton auditori perceiv extent impuls respons ir record use dummi head wear hmd irtest compar ir measur without hmd irref ten naiv listen test abil discrimin irtest irref use convolv speech signal spectral analysi show hmds decreas spectral energi sideton around hz listen abl discrimin ir conclud hmds chang sideton small perceiv extent
|
D000080310;D000076142
|
T073;T066
|
36,319,213
|
phase awar deep speech enhanc frame length algorithm latenc speech process domin frame length use fourier analysi turn limit achiev perform magnitud centric approach previous studi suggest import phase grow decreas frame length work present systemat studi contribut phase magnitud modern deep neural network dnn base speech enhanc differ frame length result indic dnns success estim phase use short frame similar better overal perform compar use longer frame thus interest modern phase awar dnns allow low latenc speech enhanc high qualiti
|
D013060;D054140
|
T061;T040;T054
|
36,319,212
|
vocal fold oscil limit mucos wave self sustain vocal fold vibrat possibl either two mechan mucos wave propag along medial surfac vocal fold vocal tract offer inert reactanc quantit comparison show mucos wave mechan lower threshold pressur higher glottal effici supraglott inert mechan assist oscil effect optim two mechan conclud optim paramet mucos wave veloc order ms diamet larynx canal epilarynx tube order cm
|
D014827;D007830
|
T023;T030
|
36,319,211
|
near infrar photoglottographi measur multipl glottal event near infrar nir photoglottographi pgg non invas method monitor glottal activ retain function convent pgg use visibl light conveni access paper investig perform comparison simultan record electroglottographi egg signal result show nir pgg detect continu transillumin glottal apertur vocal fold contact glottal time marker known glottal closur open instant detect agre correspond egg base instant infer variat glottal waveform base nir pgg reflect vertic vocal fold edg motion
|
D005931;D019651
|
T061;T023;T029
|
36,319,210
|
sonic boom measur practic implic consid ground effect microphon instal weather harden sonic boom measur recent flight test provid opportun investig effect microphon instal sonic boom waveform spectra metric level support nasa x flight test plan flight test use n wave aircraft f model studi also conduct use sourc characterist shape low boom aircraft particular interest effect receiv height boom waveform metric elev receiv posit microphon instal local ground cover type reduct db weight sound exposur level perceiv level shown ft microphon height ray elev angl measur model result describ letter
|
D013016;D000401
|
T070;T073
|
36,319,209
|
relat chang cochlear summat potenti pair click predict speech nois percept subject hear acuiti object assay human cochlear synaptopathi cs challeng develop suspect relat summat potenti sp chang differ listen cs proof concept studi young normal hear adult recruit assign lowhigh risk group cs base extend audiogram khz sps pair click vari inter click interv isol non refractori receptor compon cochlear activ abrupt increas sps pair vs singl click observ high risk listen critic exagger sps predict speech nois subject hear abil suggest relat sp chang rapid click might help identifi putat synaptopath listen
|
D013060;D013067
|
T041;T040;T054
|
36,319,207
|
isol perform metric person sound zone reproduct system two isol perform metric inter zone isol izi inter program isol ipi introduc evalu person sound zone psz system compar common use acoust contrast metric izi ipi general multichannel audio quantifi isol sound zone audio program respect two metric shown general non interchang suitabl differ scenario generat dark zone izi minim audio audio interfer ipi furthermor two exampl free field simul present demonstr applic izi ipi evalu psz perform differ render mode psz robust
|
D008962;D013016
|
T062;T170;T070
|
36,319,205
|
associ three dose bntb mrna vaccin abnorm bleed irregular menstrual cycl among premenopaus femal singl institut observ studi covid vaccin effect prevent sever case covid women gynecolog advers event menstrual irregular irregular bleed could concern covid vaccin studi investig gynecolog advers event vaccin japanes femal popul
|
D000086663;D000086382
|
T200;T047;T067
|
36,319,204
|
compar studi use risk score assess earli stage covid affect pregnanc omicron variant versus previous variant evalu util risk score assess current status prognosi covid pregnanc
|
D000086382;D011251
|
T047;T067
|
36,319,203
|
pregnanc outcom preterm prematur ruptur membran japan environ children studi evalu pregnanc outcom preterm prematur ruptur membran preterm prom pprom gestat age
|
D047928;D000022;D005322
|
T033;T047;T046
|
36,319,202
|
role p mdm signal miss abort possibl pathogenesi miss abort one common obstetr gynecolog complic angiogenesi import factor fetal placent develop howev definit etiolog pathogenesi fulli understood
|
D000030
|
T047
|
36,319,201
|
development outcom japanes preschool age children conceiv assist reproduct technolog studi aim investig development outcom japanes babi conceiv assist reproduct technolog art born age month
|
D027724;D002657
|
T061;T039;T040
|
36,319,200
|
associ vitamin level second trimest pregnanc gestat diabet mellitus hydroxyvitamin oh affect glucos metabol increas insulin secret insulin receptor express howev whether oh defici increas risk gestat diabet mellitus gdm clear report purpos studi assess relationship vitamin level second trimest pregnanc risk gdm
|
D016640
|
T047
|
36,319,199
|
efficaci discontinu use low dose aspirin week gestat prevent preeclampsia low dose aspirin lda shown reduc incid preeclampsia pe previous studi focus time lda initi studi date assess time lda discontinu studi aim evalu effect lda lda initi week gestat continu week gestat
|
D011225;D047928;D006973;D006473
|
T047;T046
|
36,319,198
|
modifi laparoscop high uterosacr ligament suspens treatment apic prolaps feasibl studi purpos studi evalu feasibl modifi laparoscop high uterosacr ligament suspens lhus women apic prolaps requir uterin preserv
|
D011788;D010535
|
T078;T060;T061
|
36,319,197
|
construct valid psychometr properti chines version citi birth trauma scale current postpartum posttraumat stress disord ptsd screen scale use china general ptsd scale compil specif pregnant women thus reflect uniqu need popul studi aim translat citi birth trauma scale citi bit chines valid psychometr characterist chines postpartum women
|
D044466;D049590
|
T101;T098;T079
|
36,319,196
|
lubric reduc perin trauma systemat review meta analysi random control trial assess effect lubric reduc perin trauma vagin deliveri
|
D022125
|
T037
|
36,319,195
|
methotrex low dose corticosteroid effect altern corticosteroid resist granulomat lobular mastiti granulomat lobular mastiti gm inflammatori breast diseas unknown etiolog studi show patient could achiev complet remiss corticosteroid excision surgeri howev patient would suffer corticosteroid resist aim report singl center experi highest number corticosteroid resist gm patient treat methotrex low dose corticosteroid
|
D008727;D008413
|
T121;T047;T109
|
36,319,194
|
reliabl valid turkish languag version core lower urinari tract symptom score purpos studi develop turkish version core lower urinari tract symptom score clss determin psychometr properti turkish subject
|
D007802;D059411
|
T184;T171
|
36,319,193
|
efficaci safeti desmopressin oral disintegr tablet g male patient nocturia japanes real world multicent clinic studi clarifi japanes real world clinic data use desmopressin g oral disintegr tablet odt male patient nocturia evalu predict factor improv nighttim frequenc
|
D053158
|
T047
|
36,319,188
|
observ cross section studi associ poor broadband provis demograph health outcom wolverhampton digit enabl woden programm associ impair digit provis access health outcom systemat studi wolverhampton digit enabl programm woden multiag collabor approach determin address digit factor may impact health social care singl depriv multiethn health economi object studi determin associ measur broadband provis demograph health outcom defin popul
|
D004470;D005006
|
T090;T098;T102
|
36,319,185
|
influenc gastroenterologist intrins motiv work burnout mediat effect work stress object analyz influenc intrins motiv work burnout mediat effect work stress method questionnair survey conduct gastroenterologist work provinc china mediat model use analyz mediat effect work stress relationship intrins motiv burnout resutl valid questionnair collect includ women men averag age intrins motiv relat reduc level burnout includ emot exhaust dehuman low sens accomplish p job stress partial mediat negat correl intrins motiv job burnout three dimens account p respect femal physician intrins motiv direct relat reduct burnout especi dimens emot exhaust direct effect account femal gastroenterologist male conclus enhanc intrins motiv gastroenterologist direct reduc burnout indirect reduc burnout allevi work stress work environ femal physician intrins motiv greater direct effect reduc burnout
|
D000072102;D002055;D000073397
|
T033;T054;T097;T048
|
36,319,184
|
clinic multicent investig analysi advers event primari anterior cruciat ligament reconstruct use ligament advanc reinforc system object investig postop advers event primari anterior cruciat ligament reconstruct aclr use ligament advanc reinforc system lar establish ground standard clinic use artifici ligament method china artifici ligament studi group calsg organ follow case aclr use lar lar aclr orthoped sport medicin center china juli decemb advers event includ cumul failur complic identifi follow studi case screen cumul failur classifi graft ruptur clinic failur graft ruptur confirm arthroscopi clinic failur confirm either limit knee rang motion extens andor flexion contralater knee control joint laxiti lachman test pivot shift test side side differ mm demograph inform clinic data cumul failur case collect cumul failur rate complic rate composit ratio differ degre joint symptom among cumul failur case composit ratio failur caus statist analyz result total case lar aclr collect center met inclus criteria studi includ case complet follow follow rate median follow time q q month nineti eight advers event identifi includ cumul failur complic cumul failur rate complic rate median cumul failur time q q month surgeri patient present joint instabl patient joint pain patient joint swell patient feel knee catch lock patient flexion restrict greater patient extens restrict greater incorrect bone tunnel posit confirm patient reinjuri patient graft ruptur confirm arthroscopi patient screw loosen occur patient complic detect patient screw relat problem confirm patient synov patient stiff patient infect patient conclus long term cumul failur rate complic rate lar aclr joint instabl pain main joint symptom cumul failur case lar aclr incorrect bone tunnel posit primari caus failur great concern clinician
|
D007593;D059549;D000070598
|
T033;T037;T061
|
36,319,183
|
efficaci safeti daratumumab patient relapsedrefractori multipl myeloma object investig efficaci safeti daratumumab relapsedrefractori multipl myeloma rrmm patient method fifti two rrmm patient treat daratumumab septemb novemb west china hospit retrospect enrol includ male femal mean age patient first diagnosi multipl myeloma year accord dosag daratumumab patient divid low dosag group n high dosag group n overal respons rate orr progress free surviv pfs overal surviv os advers event rate investig univari multivari analysi potenti factor conduct result patient receiv daratumumab monotherapi receiv daratumumab plus immuno modulatori drug imid treatment receiv daratumumab plus proteosom inhibitor pi treatment receiv daratumumab plus dexamethason treatment diagnosi age high dosag group patient year signific younger low dosag group year p baselin creatinin level high dosag group patient q q moll signific higher low dosag group moll p signific differ baselin clinic characterist previous treatment regimen previous line treatment regimen cycl daratumumab high dosag group low dosag group p orr patient orr daratumumab plus imid group signific higher monotherapi dexamethason group orr p median follow q q month median pfs overal cohort ci month median pfs daratumumab plus imid group ci month signific better monotherapi dexamethason group ci month hr ci p higher diagnosi age risk factor progress hr ci p cycl daratumumab treatment protect factor progress hr ci p signific influenc daratumumab dosag progress high dosag vs low dosag hr ci p median os overal cohort ci month higher serum calcium independ risk factor death hr ci p signific influenc daratumumab dosag death high dosag vs low dosag hr ci p advers event includ infect infus associ reaction thrombocytopenia conclus daratumumab effect treat rrmm dosag daratumumab signific influenc prognosi use combin treatment incid advers event relat low favor safeti profil
|
D009101
|
T191
|
36,319,182
|
surviv prognosi analysi patient hodgkin lymphoma treat standard treatment paradigm object analyz surviv prognosi hodgkin lymphoma hl patient receiv standard first line therapi method data clinic characterist treatment outcom patient hl diagnos cancer hospit chines academi medic scienc chcam januari st decemb st receiv standard first line treatment retrospect analyz compar hl patient receiv treatment surveil epidemiolog end result seer databas unit state period factor associ freedom progress ffp patient chcam analyz treatment surviv data patient relapsedrefractori hl rrhl fail standard first line treatment correspond period chcam collect analyz outcom salvag therapi result total hl patient chcam includ studi median age year rang year male femal februari th patient follow median time month rang month lymphoma specif surviv lss rate overal surviv os rate year hl patient chcam ci ci respect lss os rate year hl patient seer databas ci ci respect unadjust lss os rate patient chcam higher patient seer databas p two group adjust european organ research treatment cancer stage system earli stage unfavor hr ci p advanc stage hr ci p serum microglobulin hr ci p influenc factor ffp patient chcam complet remiss rate median progress free surviv pfs year pfs rate year os rate patient rrhl ci month ci month ci ci respect conclus outcom hl patient receiv standard first line treatment excel howev therapeut effect hl patient incurr diseas progress relaps standard first line treatment satisfi
|
D006689
|
T191
|
36,319,181
|
preliminari result biport endoscop lumbar interbodi fusion decompress pedicl screw insert assist endoscop techniqu lumbar spinal stenosi combin spondylolisthesi instabl object evalu preliminari clinic outcom biport endoscop lumbar interbodi fusion lif decompress pedicl screw insert assist endoscop techniqu lumbar spinal stenosi combin spondylolisthesi instabl method data patient singl level lumbar spinal stenosi underw lif decompress pedicl screw insert assist biport endoscopi xinjiang product construct corp hospit march st april th analyz retrospect visual analogu scale vas pain back leg oswestri disabl index odi patient collect oper third day oper last follow moreov oper time intra oper blood loss radiat shot pedicl screw insert post oper drainag ambul time record screw posit check ct oper result patient femal mean age year rang year patient follow week patient good clinic result vas score back pain third day oper last follow signific lower preoper vs point p vas score leg pain third day oper last follow signific lower preoper vs point p odi score last follow signific lower oper vs p intra oper blood loss ml drainag amount post oper ml oper time min ambul time day total radiat shot pedicl screw insert time averag radiat shot per screw time sever complic advers event occur nerv root injuri dural tear occur oper revis surgeri need conclus pedicl screw insert assist biport endoscop techniqu decreas radiat exposur good feasibl safeti lif lif combin pedicl screw insert assist biport endoscopi effect safe surgeri lumbar spinal stenosi good earli result
|
D013168;D013130;D065289;D013123
|
T061;T047;T074;T020
|
36,319,180
|
compar studi decompress unilater biport endoscop compar laminectomi fusion intern fixat treatment sever lumbar spinal stenosi object compar clinic efficaci unilater biport endoscopi unilater laminotomi bilater decompress ube ulbd posterior lumbar interbodi fusion plif treatment sever lumbar spinal stenosi slss method clinic data patient slss treat plif ube ulbd dalian central hospit affili dalian medic univers april april collect divid ube group plif group accord differ surgic procedur case ube group includ male femal age year patient plif group includ male femal age year oper time intraop blood loss surgic complic volum drainag transfus post oper bed rest time postop hospit stay surgic cost group record analyz visual analogu scale vas backleg pain pre oper month month month post oper oswestri disabl index odi pre oper month month month post oper use determin outcom dural sac cross section area dsca schiza grade group preoper month postop record result oper time ube group min lower plif group min p intraop blood loss drainag ube group ml ml lower pilf group ml ml p postop bed rest time hospit stay ube group day day shorter plif group day day p surgic cost also lower ube group plif group rmb thousand yuan vs thousand yuan p addit patient receiv blood transfus ube group dural sac tear occur case ube group case plif group nerv root injuri infect occur one case plif group respect plif group vas back pain signific improv day oper compar oper signific improv month month year oper p vas back pain day oper odi month oper ube group signific superior plif group p signific differ two group vas back pain month month year oper odi month year oper group got signific canal expans surgeri plif group show larger canal expans extent p conclus ulbd ube could achiev full decompress whole spinal canal limit structur damag treat slss compar plif ube ulbd could get complet decompress well less iatrogen damag may ideal altern surgic techniqu slss less invas
|
D013130;D013123
|
T061;T020
|
36,319,179
|
compar studi unilater biport endoscopi coaxial larg channel endoscopi lumbar spinal stenosi object compar efficaci unilater biport endoscopi ube coaxial larg channel endoscopi lumbar spinal stenosi method total patient lumbar spinal stenosi treat tianjin hospit march octob includ studi patient case treat ube includ male femal mean age year case treat coaxial larg channel endoscopi includ male femal averag age year visual analogu scale vas score pain oswestri disabl index odi compar surgeri two group improv rate calcul oper time intraop blood loss periop condit complic compar oper efficaci evalu accord macnab scale compar two group result signific differ age gender diseas cours vas pain odi index level two group oper p oper time postop drainag ube group coaxial larg channel endoscopi group compar min min ml ml respect p oper vas score low back pain vas score leg pain odi two group lower oper decreas continu follow repeat measur analysi varianc signific differ found differ time point p conclus ube coaxial larg channel endoscopi provid excel result lumbar spinal stenosi ube suffici decompress conveni explor remov herniat disc
|
D013130;D007405
|
T047;T020
|
36,319,178
|
characterist risk factor spinal epidur hematoma unilater biport endoscop lumbar interbodi fusion object investig incid characterist risk factor spinal epidur hematoma unilater biport endoscop ube lumbar spine surgeri method clinic data patient underw lumbar spine surgeri ube guangdong provinci peopl hospit februari march retrospect review patient male femal mean age year rang year mri imag third day post surgeri observ occurr hematoma count patient assign normal group hematoma group base presenc hematoma relat clinic indic patient collect use comparison two differ group logist stepwis regress model use analyz whether index risk factor hematoma ube lumbar fusion result total hematoma incid rate symptomat hematoma rate hematoma reoper rate univari logist regress analysi show hypertens ci diabet ci admiss systol blood pressur mmhg mmhg kpa ci platelet l ci preoper blood calcium mmhg ci preoper blood calcium mmoll ci spinal stenosi grade ci risk factor spinal hematoma ube lumbar fusion p conclus type spinal canal hematoma ube lumbar fusion includ local extend type risk factor hematoma includ high systol blood pressur admiss low preoper blood calcium sever spinal stenosi
|
D046748;D013130;D013123
|
T061;T046;T020
|
36,319,177
|
applic expans unilater biport endoscopi spine surgeri relat issu begin clinic applic unilater biport endoscopi ube main appli lumbar degen diseas lumbar disc herniat lumbar spinal stenosi account major improv technolog equip rang diseas treat continu expand indic extend cervic thorac spinal decompress also use conjunct minim invas techniqu percutan pedicl screw obliqu lumbar interbodi fusion play import role lumbar interbodi fusion howev develop unilater biport endoscop technolog still initi stage china wide appli still relev issu need clarifi studi therefor paper discuss technic superior applic expans shortcom ube techniqu relat issu
|
D016099;D008161
|
T061;T058;T029
|
36,319,176
|
analys occup status physician improv femal physician career develop right health problem physician wild concern affect career satisfact career achiev physician occup environ physician nation abroad well differ work caus gender describ behalf gastroenterolog analys pressur challeng face physician occup status differ gender understand work feel implement target improv measur futur medic environ encourag femal medic profession play better role healthcar
|
D004651;D010820
|
T033;T098;T097;T080
|
36,319,175
|
safeti efficaci new domest distal perfor stent graft treatment stanford type b aortic dissect object evalu safeti efficaci new domest distal perfor stent graft talo stent treatment stanford type b aortic dissect tbad method twenti five patient tbad treat talo stent yanan hospit affili kunm medic univers februari decemb select research subject intraop angiographi perform determin number branch arteri remain stent releas postop day pod pain intens patient evalu visual analog scale vas comput tomographi angiographi cta patient oper month month oper compar includ aortic diamet true lumen diamet fals lumen diamet level tracheal bifurc follow perform month month month month surgeri occurr stent relat advers event reoper surviv rate record result enrol patient includ male femal age year intraop angiographi show branch arteri preserv vas score pod aortic diamet level tracheal bifurc mm mm mm surgeri month month surgeri signific differ p diamet main true lumen level tracheal bifurc mm mm mm surgeri month month postop diamet main fals lumen level tracheal bifurc mm mm mm respect compar surgeri diamet true lumen increas signific month month surgeri p diamet fals lumen decreas p stent relat advers event occur within day surgeri secondari oper occur within month surgeri type type endoleak death case paraplegia report stent structur posit remain good death paraplegia case month postop stent relat advers event occur conclus use talo stent treatment tbad effect help remodel aorta preserv intercost arteri spinal arteri good clinic effect safeti
|
D019917;D000784;D057510;D017545
|
T061;T047;T046
|
36,319,174
|
long term efficaci low dose rituximab treatment patient primari membran nephropathi object explor long term efficaci low dose rituximab rtx treatment patient primari membran nephropathi pmn method patient biopsi proven pmn receiv low dose rtx initi second line regimen august may depart nephrolog tianjin medic univers general hospit respect enrol clinic paramet patient urinari protein g h serum albumin mlmin treatment respons patient pmn observ follow remiss rate patient urinari protein g h g h anti plar antibodi ruml ruml egfr mlmin mlmin analyz respect result total patient enrol includ male femal age year patient receiv rtx initi treatment patient second line therapi total median dose rtx first cours mg overal remiss rate st rd th th th month respect median overal respons time month two case relaps patient remiss n higher level baselin egfr vs mlmin p lower level urinari protein vs g h p anti plar antibodi level vs ruml p without remiss n month treatment statist signific differ remiss rate initi second line treatment p moreov patient higher remiss rate urinari protein g h group vs p anti plar antibodi ruml group vs p egfr mlmin group vs p conclus low dose rtx treatment pmn effect long term follow lower recurr rate result also suggest suitabl patient baselin urinari protein g h anti plar antibodi ruml egfr mlmin
|
D015433
|
T047
|
36,319,173
|
efficaci safeti differ dose antivir agent treatment herp zoster meta analysi object systemat evalu efficaci safeti differ dose antivir drug treatment herp zoster method pubm embas cochran librari vip cnki wanfang databas april search two review select studi accord inclus exclus criteria cochran bias risk assess tool use qualiti evalu data analyz revman softwar meta analysi qualit data use relat risk rr effect index quantit data use mean differ md effect index point estim ci effect given result fourteen random control trial patient includ studi compar mg acyclovir five time day mg improv effect rate shorten blister stop time md ci p reliev pain faster md ci p shorten scab time md ci p without increas advers reaction rate rr ci p compar mg valaciclovir twice daili mg valaciclovir three time day improv effect rate rr ci p shorten blister stop time md ci p reliev pain faster md ci p shorten scab time md ci p reduc incid postherpet neuralgia rr ci p without increas advers reaction rate rr ci p immunocompromis patient compar mg valaciclovir three time day mg signific improv treatment efficaci signific differ among efficaci mg mg mg famciclovir three time day treatment herp zoster conclus mg acyclovir five time day mg valaciclovir mg famciclovir three time day better choic treatment herp zoster
|
D000998;D006562
|
T121;T047
|
36,319,172
|
efficaci analysi lidocain plaster combin gabapentin treatment herp zoster neuralgia object evalu efficaci safeti lidocain plaster combin gabapentin treatment herp zoster neuralgia hzn method total patient diagnos hzn june januari depart pain clinic nanj drum tower hospit select gender limit divid group random number tabl method group n prescrib gabapentin alon group b n lidocain plaster alon group c n lidocain plaster combin gabapentin exclud patient meet criteria case group case group b case group c visual analogu scale vas short form mcgill pain questionnair sf mpq score drug dosag advers reaction group pre treatment post treatment one week two week four week week record evalu pittsburgh sleep qualiti index psqi score medic outcom studi short form sf score record advers reaction drug dosag group document repeat measur anova use compar curat effect three group differ time point treatment result age three group patient year old respect p proport men case case case respect p treatment vas score sf mpq score patient three group decreas time point compar treatment p vas sf mpq score patient group c time point respect lower patient group b p dosag gabapentin lidocain plaster group c lower group b time point treatment p psqi score patient three group lower treatment p psqi score patient group c lower patient group b p sf score patient three group higher treatment p sf score group c higher patient group b p incid advers reaction three group case case case respect p advers reaction group b c less group p conclus lidocain plaster combin gabapentin better analges effect treatment hzn less incid advers reaction reduc dosag system drug improv patient sleep qualiti life thus could provid safe effect method treatment hzn
|
D006562;D009437
|
T184;T047
|
36,319,171
|
studi risk factor postherpet neuralgia object analyz clinic featur risk factor herp zoster risk factor postherpet neuralgia phn method total patient diagnos herp zoster peke univers peopl hospit januari april includ patient herp zoster age patient male patient divid phn group non phn group accord whether patient herp zoster develop phn patient develop phn age male inform medic histori phn group non phn group collect inform use glucocorticoid immunosuppress agent biolog agent target medicin within month herp zoster occur histori surgeri within month herp zoster occur durat phn collect logist regress analysi use analyz risk factor phn result patient herp zoster age year intercost nerv most involv patient herp zoster total hypertens case account highest number patient chronic diseas follow diabet case coronari heart diseas case rheumatoid arthriti case account highest number patient connect tissu diseas follow sjogren syndrom case system lupus erythematosus case logist regress analysi show age year old ci lesion upper limb shoulder ci hypertens ci immunosuppress treatment ci independ risk factor phn p conclus herp zoster most occur peopl age main affect intercost nerv common complic hypertens rheumatoid arthriti age lesion upper limb shoulder hypertens immunosuppress treatment may independ risk factor phn
|
D051474;D006562;D006973;D001172
|
T047
|
36,319,170
|
hbeag negat chronic hepat b patient treat nucleo ide analogu achiev hbsag loss drug withdraw stop cure may come nucleosidenucleotid analogu nas wide use antivir treatment chronic hepat b chb howev difficult achiev serum hepat b surfac antigen hbsag loss nas therapi recent year sever prospect trail report hbsag loss function cure clinic cure also occur small number hepat b e antigen hbeag negat chb patient discontinu long term treatment nas accord stop cure strategi propos although mechan fulli elucid known factor relat serum hbsag loss nas withdraw includ hbv genotyp durat nas treatment serum hbsag hbv rna level end treatment ethnic differ review discuss best time stop nas therapi potenti marker predict relaps cessat nas possibl mechan stop cure hbeag negat chb patient propos suggest time retreat
|
D006514;D019694
|
T129;T047;T121;T116
|
36,319,169
|
interpret expert consensus whole process manag herp zoster associ pain current diagnosi treatment manag herp zoster associ pain well understood china expert consensus whole process manag herp zoster associ pain focus standard diagnosi treatment herp zoster associ pain time definit clinic stage relev detail analges drug minim invas intervent therapi valu vaccin pain manag articl give detail interpret associ content consensus
|
D006562
|
T047
|
36,319,168
|
call attent standard manag herp zoster herp zoster hz common viral diseas main affect elder popul rise incid occurr postherpet neuralgia phn domin thorni complic thus aggrav diseas burden vaccin clinic applic small molecul biolog certain diseas identifi new risk factor develop hz develop hz vaccin emerg pivot prevent measur occurr hz refin diagnosi earli standard antivir treatment hz key improv standard manag strategi
|
D006562;D051474
|
T047
|
36,319,167
|
research progress hemodynam instabl relat blood purif critic ill patient hirrthirrthirrthirrthirrt
|
D016638;D014652
|
T047
|
36,319,166
|
research progress depdc gene relat epilepsi depdcmtordepdc
|
D004827;D004828
|
T033;T047
|
36,319,165
|
case shaken babi syndrom
|
D038642
|
T037
|
36,319,164
|
two case lymphat malform caus new variat piezo gene piezocc tcc
|
D015160;D007473
|
T123;T047;T116
|
36,319,163
|
kaposiform lymphangiomatosi diagnos circul tumor dna child dnanra ca gpqr
|
D000074141;D008202;D006390;D012514
|
T191;T114
|
36,319,162
|
primari gastric diffus larg b cell lymphoma child bb
|
D005190;D016403
|
T099;T191;T062;T079;T054
|
36,319,161
|
sever case covid child min
|
D000086382
|
T047;T067
|
36,319,160
|
case neurodevelopment disord refractori epilepsi caus gria gene variant griacg tpglyval
|
D000069279;D065886
|
T047;T048
|
36,319,159
|
case infantil anti ampa receptor enceph ampaiggampaampa
|
D004660
|
T047
|
36,319,158
|
human chorion gonadotropin secret gonadoblastoma girl x turner syndrom case report literatur review object summar experi diagnosi treatment x turner syndrom ts gonad chromosom mosaic bilater gonadoblastoma gb secret human chorion gonadotrophin hcg method femal patient age year month admit hospit complaint enlarg breast month elev blood hcg month clinic data summar relat literatur march key word turner syndrom gonadoblastoma chromosom human chorion gonadotropin precoci pubm cnki wanfang databas review result girl went local hospit month breast develop age year found heart murmur diagnos pulmonari venous malform atrial septal defect secondari foramen type surgic correct perform experienc progress breast develop rapid linear growth mark advanc skelet age explain partial activ hypothalam pituitari gonad axi determin age year month local hospit whole exom sequenc reveal chromosom number abnorm x confirm karyotyp age year month serum hcg found elev ul lesion found local hospit physic examin found breast develop pubic hair develop clitoromegali elev serum testosteron gl hcg ul sex determin region sri gene negat peripher blood sampl thorac abdomin ct head pelvic magnet reson imag normal exploratori laparotomi confirm presenc left adnex tumor right fibrous streak gonad surgeri simultan sampl bilater gonad peripher venous blood obtain serum hcg estradiol testosteron concentr higher lower left gonad venous blood right gonad venous blood peripher venous blood bilater gonadectomi perform histopatholog reveal bilater gonadoblastoma sri posit bilater gonad tissu surgeri serum e testeron hcg return normal far case hcg secret gonadoblastoma report worldwid phenotyp case femal viril amenorrhea preoper peripher blood hcg concentr ul respect conclus high risk gb ts chromosom compon gb infrequ present breast develop gb associ hcg secret rare karyotyp perform phenotyp femal masculin viril ts indic presenc chromosom materi concurr androgen secret tumor
|
D018238;D014424;D010051
|
T047;T191
|
36,319,157
|
efficaci recombin human growth hormon treatment children born small gestat age syndrom non syndrom short statur object analys efficaci recombin human growth hormon rhgh treatment children born small gestat age sga syndorm non syndorm short statur method clinic data children born sga diagnos short statur admit center endocrinolog genet metabol beij children hospit juli june collect analyz accord consensus short statur divid syndrom group non syndrom group treatment month treatment height standard deviat score ht sds differ height standard deviat ht sds homeostasi model assess insulin resist index homa ir compar group ht sds homa ir compar treatment independ test kruskal walli test use comparison group pair test mann whitney u test use intra group comparison result among case male femal age year signific differ ht sds month treatment group vs p height sds month treatment vs p month treatment insulin resist index non syndrom group signific higher syndrom group vs z p signific differ ht sds month treatment month month syndrom type z p p signific differ non syndrom type month treatment month month month month month month z p conclus efficaci rhgh treatment children born sga compar syndrom non syndrom short statur case non syndrom children treat rhgh need frequent follow due risk insulin resist
|
D019382;D007333
|
T125;T121;T046;T116
|
36,319,156
|
preval risk factor medic non adher children inflammatori bowel diseas object investig preval risk factor medic non adher children inflammatori bowel diseas ibd method cross section studi conduct children hospit zhejiang univers school medicin septemb march children ibd enrol general inform medic adher parent diseas relat knowledg collect questionnair accord medic adher score children divid adher group score non adher group score demograph clinic characterist two group compar subsequ multivari binari logist regress analysi perform determin risk factor medic non adher result children male femal age year non adher group adher group regard demograph clinic characterist result show dosag frequenc parent diseas relat knowledg associ medic non adher p multivari binari logist regress analysi show compar year old children risk medic non adher signific increas children age year ci p year ci p risk also signific increas children took medic twice per day ci p compar children took medic per day meanwhil parent score questionnair crohn diseas ulcer coliti relat knowledg ci p also signific risk factor conclus medic non adher common children ibd children older year dosag frequenc twice per day parent poor diseas relat knowledg independ risk factor medic non adher children ibd clinician pay attent promot patient adher improv clinic outcom
|
D015212
|
T047
|
36,319,155
|
comparison efficaci safeti low dose rituximab regimen second line treatment primari immun thrombocytopenia children object compar efficaci safeti low dose rituximab regimen treatment children primari immun thrombocytopenia itp method total itp children admit hematolog oncolog center beij children hospit januari march enrol prospect cohort studi singl dose group rituximab given singl dose mgm maximum dose mg dose group rituximab given dose mg week bodi weight patient kg increas dosag mg week week wilcoxon mann whitney test chi squar test fisher exact test use analyz differ efficaci safeti treatment burden two group result among children male femal age medic year case singl dose group case dose groupther signific differ overal respons rate complet respons rate partial respons rate singl dose group dose group vs vs vs p singl dose group earlier get overal respons dose group vs week z p signific differ sustain respons rate overal respons rate year complet respons rate year partial respons rate year singl dose group dose group vs vs vs vs p signific differ durat overal respons recurr rate within half year one year recurr time rate advers event singl dose group dose group p number hospit durat hospit stay dosag singl dose group signific lower dose group vs time vs vs mg z p conclus singl dose rituximab regimen compar dose rituximab regimen effect safeti treatment children itp econom conveni singl dose rituximab regimen suitabl second line treatment children itp
|
D016553
|
T047
|
36,319,154
|
suitabl estim urin protein use differ estim h urin creatinin equat children glomerular diseas object assess reliabl estim urin protein predict h urin protein excret children glomerular diseas method four hundr forti three children glomerular diseas admit pediatr depart peke univers first hospit januari decemb enrol cross section studi h estim urin creatinin calcul previous describ equat h measur urin creatinin measur urin protein creatinin ratio upcr h urin protein hup urinari sediment analysi microscopi collect estim urin protein comput product measur upcr estim measur h urin creatinin spearman correl analysi bland altman analysi linear regress analysi use compar correl agreement accuraci estim urin protein hup effect urinari protein level erythrocyt number relationship analyz result children glomerular diseas age year male femal particip nephrot syndrom particip iga nephropathi particip alport syndrom particip lupus nephriti particip purpura nephropathi particip isol proteinuria spearman correl analysi show strong correl estim urin protein hup r p correl improv multipli measur upcr h measur urin creatinin r p improv correl also observ use estim urin creatinin calcul hellerstein formula ghazali barratt formula ellam formula walser formula cockcroft gault formula ix formula r p bland altman analysi show differ measur upcr hup g consist limit consist improv h measur urin creatinin correct differ g consist limit consist estim urin protein improv correct differ formula cockcroft gault formula show best consist estim urin protein hup differ g consist limit linear regress analysi show measur upcr poor accuraci predict hup r p accuraci improv h measur urin creatinin correct accuraci estim urin protein predict hup improv use differ formula cockcroft gault formula best r p increas urinari protein level decreas urinari erythrocyt number correl agreement accuraci estim urin protein measur upcr hup improv p except ellam ix formula estim urin protein use rest four formula outperform measur upcr p conclus h urin creatinin excret rate obtain cockcroft gault equat weight urin protein creatinin ratio reliabl predict hup measur upcr alon children glomerular diseas
|
D003404
|
T123;T109
|
36,319,153
|
multicent studi childhood hodgkin lymphoma treat hl regimen china object evalu efficaci hodgkin lymphoma hl regimen treatment children hl investig prognost factor childhood hl method clinic data children age year newli diagnos hl treat hl regimen tertiari referr center childhood cancer august april analyz retrospect diagnosi confirm histopatholog morpholog immunohistochem examin clinic characterist treatment outcom summar patient divid differ group accord clinic characterist kaplan meier method use surviv analysi comparison surviv rate group perform log rank test result case male femal age diagnosi year cervic lymph node enlarg case common symptom diseas patient accompani larg mass common patholog classif mix cell type case accord ann arbor stage system case stage case stage case stage case stage accord risk stratif case low risk group case medium risk group case high risk group patient case achiev earli complet remiss cr cours chemotherapi cr rate first line treatment diseas recurr progress occur case patient case surviv case die case lost follow among surviv case case continu cr state follow time month year overal surviv os event free surviv ef rate entir group respect year os ef rate patient stage lower patient stage p year os ef rate patient high risk group lower patient low risk medium risk group p year os rate patient earli cr without earli cr p ef rate patient earli cr case without earli cr case p conclus hl regimen signific effect treatment pediatr hl howev patient high risk group without earli cr prone diseas recurr progress stage without earli cr associ wors prognosi
|
D006689
|
T191
|
36,319,152
|
covid treat oral nirmatrelvir ritonavir children object summar applic experi therapeut effect nirmatrelvir ritonavir trade name paxlovid covid children method retrospect analysi perform clinic data includ collect clinic manifest clinic outcom dynam monitor blood routin hepat renal function sar cov nucleic acid result observ relat side effect treatment etc case covid treat paxlovid admit shanghai children hospit design referr hospit sar cov infect shanghai may st june st result case year age among case male case femal case mild case under diseas risk develop sever covid symptom high fever sore throat dri cough treatment paxlovid rd day symptom onset contribut symptom free day negat result sar cov nucleic acid day patient advers manifest gastrointestin tract nervous system case littl skin rash recov withdraw paxlovid three case normal hepat renal function paxlovid treatment month discharg clinic manifest post covid syndrom found case conclus paxlovid effect relat safe treatment children covid
|
D000086382;D009696
|
T123;T047;T067;T114
|
36,319,151
|
manag short term outcom neonat born mother infect sar cov omicron variant object summar manag short term outcom neonat deliv mother infect sar cov omicron variant method retrospect studi perform neonat born mother infect sar cov omicron variant admit isol ward children hospit fudan univers march th may th postnat infect control measur neonat clinic characterist short term outcom analyz divid matern symptomat group matern asymptomat group accord whether mother sar cov symptom clinic outcom compar group use rank sum test chi squar test result neonat strict infect control measur birth birth neonat male gestat age week birth weight g neonat includ ten preterm minimum gestat age week six neonat respiratori difficulti prematur requir mechan ventil neonat test negat sar cov nucleic acid daili nasal swab first day total mother case twin pregnanc infect sar cov omicron variant time confirm sar cov infect deliveri day among case show clinic symptom none need intens care treatment peripher white blood cell count neonat matern symptomat group signific higher matern symptomat group vs l z p conclus neonat mother infect sar cov omicron variant third trimest benign short term outcom without intrauterin infect vertic transmiss strict infect control measur birth birth effect protect neonat sar cov infect
|
D000086382;D011251
|
T047;T067
|
36,319,150
|
clinic characterist neonat infect sar cov omicron variant outbreak object analyz clinic characterist neonat infect sar cov omicron outbreak shanghai method retrospect case seri studi neonat sar cov omicron infect admit neonat unit shanghai public health clinic center march st may st enrol epidemiolog histori clinic manifest nucleic acid cycl threshold ct valu outcom analyz base matern vaccin divid vaccin group unvaccin group rank sum test chi squar test use comparison group result among neonat male femal infant full term infect confirm age day neonat histori exposur infect famili member thus horizont transmiss primari mode four infant asymptomat symptomat sever critic case common clinic manifest fever case highest temperatur cours day clinic manifest includ nasal obstruct case runni nose case cough case poor feed case vomit case mild tachypnea case complet blood count neonat within normal rang c reactiv protein increas slight infant chest imag perform infant show mild focal exud chang nucleic acid turn negat ct valu within day diagnosi neonat fulli recov support treatment length hospit day telephon follow week discharg case infant show reoccurr clinic manifest nucleic acid reactiv matern vaccin signific correl symptomat infect persist posit nucleic acid result neonat p conclus horizont transmiss primari mode neonat sar cov omicron infect neonat infect usual mild asymptomat good short term outcom clinic manifest laboratori examin nonspecif
|
D000086382;D009696
|
T123;T047;T067;T114
|
36,319,149
|
diagnost valu rapid antigen test detect sar cov infect object investig diagnost valu rapid antigen test base colloid gold immunochromatograph assay detect sar cov infect symptomat patient method may june hospit children accompani famili member confirm sar cov infect covid isol unit children hospit fudan univers design referr hospit sar cov infect shanghai enrol nasopharyng swab specimen consecut collect sampl test sar cov nucleic acid real time quantit sar cov antigen test immunochromatographi correl antigen detect result chang cycl threshold ct valu evalu well sensit specif sar cov antigen detect differ period onset diseas kappa consist test conduct investig consist diagnost method result enrol sar cov symptomat infect children includ male femal age year accompani famili includ male femal age year sampl simultan test sar cov antigen nucleic acid period diseas onset negat convers viral nucleic acid overal sensit rapid antigen test specif antigen test nucleic acid test show moder consist p day onset sensit specif sar cov antigen test respect ct valu nasopharyng swab day respect conclus sar cov antigen test patient sar cov infect show accept sensit specif within day onset diseas sensit posit correl viral load negat correl onset time
|
D000086382;D009696
|
T123;T047;T067;T114
|
36,319,148
|
analysi clinic imag featur case linear scleroderma en coup de sabr central nervous system involv children object summar clinic imag featur linear scleroderma en coup de saber lscs central nervous system involv children method clinic data clinic manifest imag featur children diagnos lscs central nervous system involv admit beij children hospit affili capit medic univers may novemb retrospect analyz result patient femal age year time diagnosi age year time discoveri facial skin lesion facial skin lesion appear neurolog symptom case neurolog symptom appear month skin lesion case patient sword wound skin lesion forehead alopecia neurolog manifest includ epilept seizur case focal neurolog defect case headach case intracrani lesion ipsilater skin lesion magnet reson imag mri case show abnorm signal main involv white matter hemispher case show local encephalomalacia scatter low signal observ case suscept weight imag local brain parenchyma leptomening enhanc seen gadolinium enhanc sequenc case scatter foci calcif affect side seen cranial ct case skin biopsi perform case part lesion brain remov case patholog find suggest small vascul consist skin patholog chang patient receiv symptomat treatment antiepilept drug oral prednison combin methotrex given case case given oral prednison one case presum rest stage diseas due signific cerebr atrophi half brain antiepilept drug ad patient follow month skin lesion scleroderma alopecia progress case hemifaci atrophi develop case consid combin parri romberg syndrom seizur control case one case reduc seizur frequenc left hemiplegia one patient still intract epilepsi paroxysm headach conclus lscs central nervous system involv common girl seizur neurolog defect main manifest intracrani lesion most ipsilater skin lesion cerebr microble calcif encephalomalacia foci common patholog chang skin intracrani lesion consist small vessel vascul prednison combin methotrex treatment shown efficaci children remain refractori epilepsi neurolog deficit symptom
|
D012594;D000069279;D002114;D004678
|
T047;T046
|
36,319,147
|
genet clinic phenotyp epilepsi associ chromosom q microdelet object summar genet clinic phenotyp epilepsi children q microdelet method patient q microdelet retrospect collect pediatr depart peke univers first hospit march juli featur clinic manifest electroencephalogram eeg neuroimag analyz result patient q microdelet includ patient de novo copi number variat cnv delet size rang mb main pathogen gene region scna scna ttcb scna scna gene among patient boy girl onset age epilepsi month multipl seizur type observ includ focal seizur patient general tonic clonic seizur gtcs patient myoclon seizur patient epilept spasm patient tonic seizur patient seizur fever sensit patient status epilepticus observ patient one case normal mental motor develop case differ degre development delay six patient craniofaci abnorm six finger deform right thumb multipl system abnorm eeg show focal discharg case multifoc discharg case multifoc general discharg case brain magnet reson imag mri show enlarg subarachnoid space frontal tempor region patient enlarg later ventricl patient delay myelin white matter patient dravet syndrom diagnos case age last follow year patient seizur free longer year patient still seizur conclus epilepsi associ q microdelet main induc delet scna scna scna gene seizur onset age q microdelet relat epilepsi infanc multipl seizur type observ common seizur type includ focal seizur gtcs patient fever sensit status epilepticus patient development delay phenotyp patient delet scna scna gene sever patient delet scna gene
|
D000015;D004831;D004827;D013226
|
T033;T019;T047
|
36,319,146
|
clinic follow analysi multidisciplinari treatment children spinal muscular atrophi object analyz follow clinic effect multidisciplinari treatment children spinal muscular atrophi sma method clinic data includ nutrit status respiratori function bone health motor function children sma receiv multidisciplinari manag year follow children hospit zhejiang univers school medicin juli octob retrospect collect comparison manag perform use pair sampl test wilcoxon rank sum test etc result age patient boy girl month enrol case type case type case type respect multidisciplinari manag case sma patient malnutrit decreas p level vitamin signific increas vs nmoll p cobb angl scoliosi also improv signific vs z p hammersmith function motor scale expand score children sma type type show signific elev vs score vs score z p conclus multidisciplinari manag benefici delay progress multi system impair sma patient malnutrit restrict ventil dysfunct scoliosi
|
D012600;D009134;D044342
|
T047
|
36,319,145
|
expert consensus clinic manag neonat seizur
|
D004827;D007232
|
T033;T047
|
36,319,144
|
guidelin diagnosi treatment manag urea cycl disord china
|
D056806;D020163
|
T047
|
36,319,143
|
chines practic guidelin clinic issu relat hormon therapi children development epilept encephalopathi deede dee
|
D013036
|
T033;T047
|
36,319,142
|
manag strategi practic sar cov infect children hospit
|
D000086382
|
T047;T067
|
36,319,141
|
diagnosi treatment strategi sever covid children omicron
|
D000086382
|
T047;T067
|
36,319,140
|
strengthen treatment sar cov infect children under diseas omicron
|
D000086382
|
T047;T067
|
36,319,139
|
diagnosi treatment rare pediatr neurogenet diseas enter diseas modifi therapi era
|
D035583
|
T047
|
36,319,138
|
advanc neoadjuv immunotherapi local advanc head neck squamous cell carcinoma head neck squamous cell carcinomahnscchnsccimmun checkpoint inhibitorsicishnscchnsccici icishnscc
|
D006258;D002294
|
T191
|
36,319,137
|
progress diagnosi treatment ectop pituitari adenoma ectop pituitari adenomaepaepaepa
|
D010911
|
T191
|
36,319,136
|
research advanc hear impair alzheim diseas
|
D000544;D034381
|
T033;T047;T048
|
36,319,135
|
progress link hereditari deaf chromosom sequenc yyyyyyyyy
|
D003638;D006319
|
T033;T184;T047
|
36,319,133
|
thyroid metastasi hepatocellular carcinoma case report
|
D006528;D008113;D013964;D016609
|
T191
|
36,319,132
|
hybird rosai dorfman diseas involv bilater nasal caviti cervic lymph node one case report rosai dorfman rosai dorfman
|
D015618;D042601
|
T047;T023
|
36,319,131
|
intraven gadolinium enhanc inner ear mri patient mnire diseas vertigo attack
|
D008575;D007758
|
T047;T023
|
36,319,130
|
hsacirc affect progress tongu squamous cell carcinoma activ wnt catenin signal pathway object explor action mechan hsacirc occurr develop tongu squamous cell carcinoma tscc method tissu sampl tscc patient examin patient includ male femal age year old underw surgeri affili hospit nantong univers affili tumor hospit nantong univers decemb decemb saliva sampl obtain healthi volunt male femal age year old tscc patient tscc cell line cal tca hn use express level hsacirc pair fresh match tscc para carcinoma tissu sampl pair saliva sampl tscc cell line detect quantit real time polymeras chain reaction qrt pcr hsacirc gene interfer lentivir transfect construct hsacirc tscc cell line cal tca knock express hsacirc hsacirc interfer group sh circ load lentivirus group negat control test qrt pcr cell highest knock effici select cck test coloni format assay transwel invas assay scratch assay express emt relat protein includ e cadherin snail protein n cadherin vimentin protein relat wnt catenin signal pathway includ catenin c myc bcl mmp cyclin measur western blot tscc cell interfer group co cultur wnt catenin pathway activ licl express protein measur western blot tscc cell interfer group control group subcutan inject nude mice compar effect hsacirc knockdown growth tumor graft subcutan nude mice statist analysi softwar use data analysi test chi squar test use comparison group result hsacirc high express tissu saliva sampl tscc patient cell line cal tca hn lowli express pair para carcinoma tissu saliva sampl healthi peopl normal human oral keratinocyt p log rank univari analysi show hsacirc express level tumor differenti degre stage relat surviv tscc patient p multivari cox risk regress model analysi suggest hsacirc express level p stage p independ factor poor prognosi tscc patient western blot show express snail protein n cadherin vimentin regul e cadherin regul interfer group compar control group interfer group express catenin c myc bcl mmp cyclind regul revers tscc cell co cultur licl knockdown hsacirc reduc prolifer invas metastasi abil cal tca cell revers tscc cell co cultur licl growth rate volum tumor graft subcutan interfer group use licl greater negat control group conclus hsacirc independ prognost factor tscc high express hsacirc promot prolifer invas metastasi tscc cell
|
D014062;D002294
|
T191
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.